Loading...
Loading...
Browse all stories on DeepNewz
VisitMarket adoption rate of Shield test in the first year
Below 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
Above 50% • 25%
Company financial reports, healthcare industry analysis reports
FDA Panel Recommends Approval of Guardant Health's Shield Blood Test, Stock Jumps 18.6%
May 23, 2024, 10:20 PM
An independent panel of advisers to the U.S. Food and Drug Administration (FDA) has recommended the approval of Guardant Health's blood-based test for detecting colorectal cancer. The test, known as the Shield test, is designed to screen for colon and rectal cancers and has been endorsed by the FDA advisory panel as a non-invasive screening option. The panel voted by large majorities that the test is safe and effective, and that its benefits outweighed its risks. If approved, it will be the first blood screening test for colorectal cancer that meets the requirements for Medicare reimbursement. The panel's recommendation marks a significant step towards FDA approval, although colonoscopies remain the gold standard for diagnosing colon cancers. Guardant Health's stock saw a significant increase of 18.6% in pre-market trading following the panel's endorsement.
View original story
Less than 25% • 25%
25%-50% • 25%
51%-75% • 25%
More than 75% • 25%
< 10% adoption • 33%
10% to 30% adoption • 33%
> 30% adoption • 33%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Below 10% • 25%
10% to 30% • 25%
31% to 50% • 25%
Above 50% • 25%
Under 25% • 33%
25-50% • 33%
Over 50% • 33%
Above 50% • 25%
30% to 50% • 25%
10% to 30% • 25%
Below 10% • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 33%
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
High Adoption • 33%
Moderate Adoption • 33%
Low Adoption • 34%
High adoption by healthcare sector • 25%
High adoption by agricultural sector • 25%
Low adoption by healthcare sector • 25%
Low adoption by agricultural sector • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%